In vivo translation of a dual-stimuli-responsive drug carrier based on mesoporous silica nanoparticles for the co-delivery of camptothecin and 5-fluorouracil

Key Points

• The aim is to develop a nanocarrier for the co-delivery of cancer drugs to reduce toxicity and enhance treatment efficacy.
• Developed a biotin-targeted mesoporous silica nanocarrier.
• Tested the sequential delivery of camptothecin and 5-fluorouracil.
• Evaluated the effectiveness in suppressing tumours while monitoring hepatic toxicity.
• Demonstrated significant tumour suppression using the dual-drug system.
• Observed reduced hepatic toxicity compared to traditional methods.